Pharma-to-physician social media and app marketing will soar by 2018: report

Doctor and digital devices
Pharma companies are shifting to social media and mobile apps to reach physicians.

Pharma companies’ marketing communications to their target audience of healthcare providers are increasingly digital. That's not terribly surprising, considering the uptake in digital channels among physicians for professional use.

What is changing, however, is the way pharma reaches doctors, according to an annual report from from healthcare and pharma solutions provider Indegene. In 2016 in the U.S., brand promotional emails, healthcare provider portals and key opinion leader webinars are the top three ways pharma companies reach out. However, by 2018, KOL webinars, social media and mobile apps will top the list, with social media and mobile apps growing the fastest, by 50% and 27%, respectively.

The social media investment is already underway, which will power the expected usage jump, Urvi Mehta, senior manager, strategic relationships at Indegene, told FiercePharma.

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

“Social media is a very powerful channel that can help in understanding the end consumers. It’s easy to make marketing decisions like segmentation, course of patient education, and influence adherence through listening and analysis of the social behavior,” she said.

While KOL webinar growth will be smaller at 8.8%, that channel was identified as the best return-on-investment generator by the more than 100 global pharma and life science companies that responded to the survey.

ROI, in fact, is an ongoing concern. Even among the rise in projected spending, seven out of 10 pharma companies noted that demonstrating ROI is the biggest barrier when implementing new communication strategies.

U.S. pharma companies are second globally in digital spending, with 31% of companies spending more than 20% of their budgets on digital. By 2018, Indegene expects that to increase to 40% of companies. China leads with 33% of its pharma companies spending more than 20% on digital, and that figure is expected to rise to 50% by 2018.

Suggested Articles

At one point, Novartis even offered up $90 apiece for the inclisiran developer but would later say even $85 was too much, a securities filing shows.

Sanofi spent months hyping its Tuesday investor event, and new CEO Paul Hudson certainly laid out a different vision for the drugmaker at the confab.

After more than 10 years as partners, Sanofi and Regeneron are splitting up their deal to comarket PCSK9 med Praluent and immunology drug Kevzara.